Stock News

Thermo Fisher Scientific (TMO) Shareholder Bristol John W & Company Increased Holding; Sio Capital Management Increases Holding in Xencor (XNCR)

Thermo Fisher Scientific Inc. (NYSE:TMO) Logo

Sio Capital Management Llc increased its stake in Xencor Inc (XNCR) by 232.27% based on its latest 2017Q4 regulatory filing with the SEC. Sio Capital Management Llc bought 76,881 shares as the company’s stock rose 30.17% while stock markets declined. The institutional investor held 109,981 shares of the health care company at the end of 2017Q4, valued at $2.41 million, up from 33,100 at the end of the previous reported quarter. Sio Capital Management Llc who had been investing in Xencor Inc for a number of months, seems to be bullish on the $1.97 billion market cap company. The stock increased 3.24% or $1.11 during the last trading session, reaching $35.34. About 332,637 shares traded. Xencor, Inc. (NASDAQ:XNCR) has risen 17.37% since May 21, 2017 and is uptrending. It has outperformed by 5.82% the S&P500.

Bristol John W & Company Inc increased its stake in Thermo Fisher Scientific Inc (TMO) by 8.53% based on its latest 2017Q4 regulatory filing with the SEC. Bristol John W & Company Inc bought 28,375 shares as the company’s stock rose 8.51% while stock markets declined. The institutional investor held 360,989 shares of the industrial machinery and components company at the end of 2017Q4, valued at $68.55M, up from 332,614 at the end of the previous reported quarter. Bristol John W & Company Inc who had been investing in Thermo Fisher Scientific Inc for a number of months, seems to be bullish on the $87.20 billion market cap company. The stock increased 0.83% or $1.79 during the last trading session, reaching $216.73. About 839,157 shares traded. Thermo Fisher Scientific Inc. (NYSE:TMO) has risen 33.66% since May 21, 2017 and is uptrending. It has outperformed by 22.11% the S&P500.

Since December 12, 2017, it had 1 buying transaction, and 6 sales for $2.82 million activity. Foster Paul A also sold $125,050 worth of Xencor, Inc. (NASDAQ:XNCR) shares. 9,215 Xencor, Inc. (NASDAQ:XNCR) shares with value of $191,280 were bought by STAFFORD JOHN S III.

More important recent Xencor, Inc. (NASDAQ:XNCR) news were published by: Seekingalpha.com which released: “Xencor down 6.8% post Q1 results” on May 08, 2018, also Seekingalpha.com published article titled: “Xencor’s (XNCR) CEO Bassil Dahiyat on Q1 2018 Results – Earnings Call Transcript”, Streetinsider.com published: “Omega’s 13F Shows Increase in Ocwen (OCN), Synchrony (SYF), United (UAL), Exits Zynga (ZNGA) (More…)” on May 15, 2018. More interesting news about Xencor, Inc. (NASDAQ:XNCR) was released by: Nasdaq.com and their article: “Market Trends Toward New Normal in LRAD, Xencor, QuinStreet, Old Second, WesBanco, and Invitae — Emerging …” with publication date: May 04, 2018.

Among 8 analysts covering Xencor (NASDAQ:XNCR), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Xencor had 24 analyst reports since August 5, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, February 22 by Cantor Fitzgerald. The firm has “Buy” rating by Canaccord Genuity given on Monday, November 13. Piper Jaffray maintained Xencor, Inc. (NASDAQ:XNCR) rating on Thursday, March 15. Piper Jaffray has “Buy” rating and $40.0 target. On Sunday, November 12 the stock rating was maintained by Piper Jaffray with “Buy”. The rating was maintained by Piper Jaffray with “Buy” on Monday, March 26. The stock has “Overweight” rating by Piper Jaffray on Tuesday, October 4. Canaccord Genuity maintained it with “Buy” rating and $38 target in Wednesday, May 9 report. Canaccord Genuity initiated Xencor, Inc. (NASDAQ:XNCR) rating on Tuesday, December 22. Canaccord Genuity has “Buy” rating and $20 target. The stock of Xencor, Inc. (NASDAQ:XNCR) has “Buy” rating given on Wednesday, March 28 by Leerink Swann. The rating was maintained by Wedbush on Monday, March 19 with “Outperform”.

Investors sentiment increased to 1.21 in 2017 Q4. Its up 0.31, from 0.9 in 2017Q3. It improved, as 15 investors sold XNCR shares while 28 reduced holdings. 15 funds opened positions while 37 raised stakes. 36.52 million shares or 1.10% more from 36.12 million shares in 2017Q3 were reported. Savings Bank Of Ny Mellon Corporation has 173,433 shares for 0% of their portfolio. Redmile Grp Lc accumulated 1.35 million shares. Ecor1 Lc owns 112,976 shares for 0.28% of their portfolio. Lord Abbett And Com Lc reported 0.02% of its portfolio in Xencor, Inc. (NASDAQ:XNCR). Perceptive Advsr Lc, New York-based fund reported 1.31 million shares. Vanguard Group Inc Inc holds 0% of its portfolio in Xencor, Inc. (NASDAQ:XNCR) for 1.80 million shares. Ameritas Inv Prtn accumulated 0% or 3,040 shares. Artal Gru Sa reported 0.03% stake. Credit Suisse Ag reported 0% in Xencor, Inc. (NASDAQ:XNCR). Arrowmark Colorado Limited Liability holds 583,491 shares or 0.13% of its portfolio. Primecap Mngmt Ca invested in 0.1% or 6.16 million shares. Atlantic Tru Gru Ltd Liability, Georgia-based fund reported 33,563 shares. Moreover, D E Shaw has 0% invested in Xencor, Inc. (NASDAQ:XNCR). Northern Tru Corporation reported 476,821 shares. State Street has 1.04M shares for 0% of their portfolio.

Sio Capital Management Llc, which manages about $116.75M and $177.32M US Long portfolio, decreased its stake in Rigel Pharmaceuticals Inc (NASDAQ:RIGL) by 678,252 shares to 885,055 shares, valued at $3.43 million in 2017Q4, according to the filing. It also reduced its holding in Puma Biotechnology Inc (NYSE:PBYI) by 15,012 shares in the quarter, leaving it with 12,209 shares, and cut its stake in Quotient Ltd (NASDAQ:QTNT).

Bristol John W & Company Inc, which manages about $6.27B and $3.53B US Long portfolio, decreased its stake in Jpmorgan Chase & Co (NYSE:JPM) by 49,282 shares to 1.07 million shares, valued at $114.79M in 2017Q4, according to the filing. It also reduced its holding in Mastercard Incorporated (NYSE:MA) by 29,270 shares in the quarter, leaving it with 658,494 shares, and cut its stake in Air Prods & Chems Inc (NYSE:APD).

More news for Thermo Fisher Scientific Inc. (NYSE:TMO) were recently published by: Seekingalpha.com, which released: “Key events next week – healthcare” on May 18, 2018. Streetinsider.com‘s article titled: “Glenview Capital Enters AmerisourceBergen (ABC), Express Scripts (ESRX), T-Mobile (TMUS) (more…) -13F” and published on May 15, 2018 is yet another important article.

Among 19 analysts covering Thermo Fisher Scientific (NYSE:TMO), 18 have Buy rating, 0 Sell and 1 Hold. Therefore 95% are positive. Thermo Fisher Scientific had 63 analyst reports since July 24, 2015 according to SRatingsIntel. The rating was maintained by Leerink Swann with “Outperform” on Monday, October 9. The stock of Thermo Fisher Scientific Inc. (NYSE:TMO) has “Buy” rating given on Wednesday, October 11 by Cowen & Co. The firm has “Buy” rating given on Tuesday, May 3 by Mizuho. The stock of Thermo Fisher Scientific Inc. (NYSE:TMO) has “Hold” rating given on Friday, April 29 by Jefferies. The stock has “Hold” rating by Jefferies on Thursday, February 1. The rating was initiated by Goldman Sachs with “Buy” on Tuesday, September 26. On Thursday, July 20 the stock rating was upgraded by Cleveland to “Buy”. On Monday, October 23 the stock rating was maintained by Robert W. Baird with “Buy”. The stock of Thermo Fisher Scientific Inc. (NYSE:TMO) earned “Buy” rating by Robert W. Baird on Monday, October 2. BTIG Research reinitiated it with “Buy” rating and $180 target in Friday, July 22 report.

Thermo Fisher Scientific Inc. (NYSE:TMO) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *